Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction
- PMID: 31319912
- DOI: 10.1016/j.jacc.2019.04.063
Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction
Abstract
Background: Fulminant myocarditis (FM) is a form of acute myocarditis characterized by severe left ventricular systolic dysfunction requiring inotropes and/or mechanical circulatory support. A single-center study found that a patient with FM had better outcomes than those with acute nonfulminant myocarditis (NFM) presenting with left ventricular systolic dysfunction, but otherwise hemodynamically stable. This was recently challenged, so disagreement still exists.
Objectives: This study sought to provide additional evidence on the outcome of FM and to ascertain whether patient stratification based on the main histologic subtypes can provide additional prognostic information.
Methods: A total of 220 patients (median age 42 years, 46.3% female) with histologically proven acute myocarditis (onset of symptoms <30 days) all presenting with left ventricular systolic dysfunction were included in a retrospective, international registry comprising 16 tertiary hospitals in the United States, Europe, and Japan. The main endpoint was the occurrence of cardiac death or heart transplantation within 60 days from admission and at long-term follow-up.
Results: Patients with FM (n = 165) had significantly higher rates of cardiac death and heart transplantation compared with those with NFM (n = 55), both at 60 days (28.0% vs. 1.8%, p = 0.0001) and at 7-year follow-up (47.7% vs. 10.4%, p < 0.0001). Using Cox multivariate analysis, the histologic subtype emerged as a further variable affecting the outcome in FM patients, with giant cell myocarditis having a significantly worse prognosis compared with eosinophilic and lymphocytic myocarditis. In a subanalysis including only adults with lymphocytic myocarditis, the main endpoints occurred more frequently in FM compared with in NFM both at 60 days (19.5% vs. 0%, p = 0.005) and at 7-year follow up (41.4% vs. 3.1%, p = 0.0004).
Conclusions: This international registry confirms that patients with FM have higher rates of cardiac death and heart transplantation both in the short- and long-term compared with patients with NFM. Furthermore, we provide evidence that the histologic subtype of FM carries independent prognostic value, highlighting the need for timely endomyocardial biopsy in this condition.
Keywords: acute myocarditis; endomyocardial biopsy; eosinophilic myocarditis; fulminant myocarditis; giant cell myocarditis; outcome.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Fulminant Myocarditis: Evolving Diagnosis, Evolving Biology, Evolving Prognosis.J Am Coll Cardiol. 2019 Jul 23;74(3):312-314. doi: 10.1016/j.jacc.2019.05.026. J Am Coll Cardiol. 2019. PMID: 31319913 No abstract available.
Similar articles
-
Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis.Circulation. 2017 Aug 8;136(6):529-545. doi: 10.1161/CIRCULATIONAHA.117.026386. Epub 2017 Jun 2. Circulation. 2017. PMID: 28576783
-
[Long term prognosis of fulminant myocarditis and predictors related to impaired cardiac function post discharge].Zhonghua Xin Xue Guan Bing Za Zhi. 2022 Mar 24;50(3):263-269. doi: 10.3760/cma.j.cn112148-20211206-01056. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 35340145 Chinese.
-
Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.N Engl J Med. 2000 Mar 9;342(10):690-5. doi: 10.1056/NEJM200003093421003. N Engl J Med. 2000. PMID: 10706898
-
Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment.Curr Cardiol Rep. 2018 Sep 26;20(11):114. doi: 10.1007/s11886-018-1054-z. Curr Cardiol Rep. 2018. PMID: 30259175 Review.
-
Fulminant Myocarditis: Epidemiology, Pathogenesis, Diagnosis, and Management.Am J Cardiol. 2019 Dec 15;124(12):1954-1960. doi: 10.1016/j.amjcard.2019.09.017. Epub 2019 Sep 25. Am J Cardiol. 2019. PMID: 31679645 Review.
Cited by
-
Cardiac magnetic resonance abnormalities in patients with acute myocarditis proven by septal endomyocardial biopsy.Clin Res Cardiol. 2023 Mar;112(3):392-400. doi: 10.1007/s00392-022-02103-1. Epub 2022 Sep 16. Clin Res Cardiol. 2023. PMID: 36112234
-
Effects of Cardioprotective Drugs on 90-Day Mortality or Heart Transplantation in Patients With Fulminant Myocarditis.Circ Rep. 2024 Jul 5;6(8):322-332. doi: 10.1253/circrep.CR-24-0059. eCollection 2024 Aug 9. Circ Rep. 2024. PMID: 39132328 Free PMC article.
-
Case report: Electrocardiographic changes in pembrolizumab-induced fatal myocarditis.Front Immunol. 2023 Feb 16;14:1078838. doi: 10.3389/fimmu.2023.1078838. eCollection 2023. Front Immunol. 2023. PMID: 36875060 Free PMC article.
-
State-of-the-Art of Endomyocardial Biopsy on Acute Myocarditis and Chronic Inflammatory Cardiomyopathy.Curr Cardiol Rep. 2022 May;24(5):597-609. doi: 10.1007/s11886-022-01680-x. Epub 2022 Feb 24. Curr Cardiol Rep. 2022. PMID: 35201561 Free PMC article. Review.
-
Fulminant Giant Cell Myocarditis vs. Lymphocytic Myocarditis: A Comparison of Their Clinical Characteristics, Treatments, and Outcomes.Front Cardiovasc Med. 2021 Dec 3;8:770549. doi: 10.3389/fcvm.2021.770549. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34926619 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
